急性骨髄性白血病に対する分子標的治療薬
急性骨髄性白血病（acute myeloid leukemia：AML）の分子病態の解明により，種々の新規分子標的薬が開発されている．FLT3阻害薬やIDH1/2阻害薬のように特定のドライバー遺伝子変異に対する標的薬（actionable mutation）と，BCL2阻害薬やSMO阻害薬のように遺伝子変異に依存せず，広くAMLに共有される機能分子に対する阻害薬（broad approach），さらに抗体医薬（CD47抗体，TIM3抗体）も開発されている．詳細なマルチオミクス解析の導入により，新たな治療標的分子の同定と新規薬剤の開発が進められ，従来の予後分類に基づいた画一的な治療からAML個別...
Saved in:
| Published in | 日本内科学会雑誌 Vol. 111; no. 6; pp. 1186 - 1192 |
|---|---|
| Main Authors | , |
| Format | Journal Article |
| Language | Japanese |
| Published |
一般社団法人 日本内科学会
10.06.2022
|
| Subjects | |
| Online Access | Get full text |
| ISSN | 0021-5384 1883-2083 |
| DOI | 10.2169/naika.111.1186 |
Cover
| Abstract | 急性骨髄性白血病（acute myeloid leukemia：AML）の分子病態の解明により，種々の新規分子標的薬が開発されている．FLT3阻害薬やIDH1/2阻害薬のように特定のドライバー遺伝子変異に対する標的薬（actionable mutation）と，BCL2阻害薬やSMO阻害薬のように遺伝子変異に依存せず，広くAMLに共有される機能分子に対する阻害薬（broad approach），さらに抗体医薬（CD47抗体，TIM3抗体）も開発されている．詳細なマルチオミクス解析の導入により，新たな治療標的分子の同定と新規薬剤の開発が進められ，従来の予後分類に基づいた画一的な治療からAML個別化医療の展開が期待される． |
|---|---|
| AbstractList | 急性骨髄性白血病（acute myeloid leukemia：AML）の分子病態の解明により，種々の新規分子標的薬が開発されている．FLT3阻害薬やIDH1/2阻害薬のように特定のドライバー遺伝子変異に対する標的薬（actionable mutation）と，BCL2阻害薬やSMO阻害薬のように遺伝子変異に依存せず，広くAMLに共有される機能分子に対する阻害薬（broad approach），さらに抗体医薬（CD47抗体，TIM3抗体）も開発されている．詳細なマルチオミクス解析の導入により，新たな治療標的分子の同定と新規薬剤の開発が進められ，従来の予後分類に基づいた画一的な治療からAML個別化医療の展開が期待される． |
| Author | 宮本, 敏浩 菊繁, 吉謙 |
| Author_xml | – sequence: 1 fullname: 宮本, 敏浩 organization: 金沢大学医薬保健研究域医学系・血液内科学 – sequence: 1 fullname: 菊繁, 吉謙 organization: 九州大学病院・遺伝子・細胞療法部 |
| BookMark | eNo9j7tKA0EYhQeJYIxpfYuN-8_MTv4tNXiDgI3WyzgX3Rij7KaxS0KUgI2VsnYWYjCKYCv6Mkt2k7cwRrE4Fzhw4FsmhdZZyxCyCm6FgvDXWjI8kRUAmAnFAikCInOoi6xAiq5LwfEY8iVSjuPw0OVMeAiMF4mfdR6zztP0eTgd9WclTz4nD5387jLtjsZvX2k3SXvX48HV-PUmGyb5fT97_8iT3uT2ZYUsWtmMTfkvS-Rga3O_tuPU97Z3a-t1p0E9YI5yteaKWa3AU5ZZtAw8XwiNWlQ1UoqG-hIMcGV4FT0AZSxqXmXcImpkJbLx-9uI2_LIBOdReCqji0BG7VA1TTAnD2bkgZj7D___qI5lFDQk-wYgdGnv |
| ContentType | Journal Article |
| Copyright | 2022 一般社団法人 日本内科学会 |
| Copyright_xml | – notice: 2022 一般社団法人 日本内科学会 |
| DOI | 10.2169/naika.111.1186 |
| DatabaseTitleList | |
| DeliveryMethod | fulltext_linktorsrc |
| Discipline | Medicine |
| EISSN | 1883-2083 |
| EndPage | 1192 |
| ExternalDocumentID | article_naika_111_6_111_1186_article_char_ja |
| GroupedDBID | ALMA_UNASSIGNED_HOLDINGS DIK F5P JSF OK1 RJT |
| ID | FETCH-LOGICAL-j2513-c0dd4c3fdc15cf3f8f315966d8d67d8228e29a1e14ce478511cef8d4734f88d83 |
| ISSN | 0021-5384 |
| IngestDate | Wed Sep 03 06:30:41 EDT 2025 |
| IsDoiOpenAccess | true |
| IsOpenAccess | true |
| IsPeerReviewed | false |
| IsScholarly | true |
| Issue | 6 |
| Language | Japanese |
| LinkModel | OpenURL |
| MergedId | FETCHMERGED-LOGICAL-j2513-c0dd4c3fdc15cf3f8f315966d8d67d8228e29a1e14ce478511cef8d4734f88d83 |
| OpenAccessLink | https://www.jstage.jst.go.jp/article/naika/111/6/111_1186/_article/-char/ja |
| PageCount | 7 |
| ParticipantIDs | jstage_primary_article_naika_111_6_111_1186_article_char_ja |
| PublicationCentury | 2000 |
| PublicationDate | 20220610 |
| PublicationDateYYYYMMDD | 2022-06-10 |
| PublicationDate_xml | – month: 06 year: 2022 text: 20220610 day: 10 |
| PublicationDecade | 2020 |
| PublicationTitle | 日本内科学会雑誌 |
| PublicationTitleAlternate | 日内会誌 |
| PublicationYear | 2022 |
| Publisher | 一般社団法人 日本内科学会 |
| Publisher_xml | – name: 一般社団法人 日本内科学会 |
| References | 12) Wei AH, et al: Venetoclax plus LDAC for newly diagnosed AML ineligible for intensive chemotherapy: a phase 3 randomized placebo-controlled trial. Blood 135 (24): 2137-2145, 2020. 5) Stone RM, et al: Midostaurin plus Chemotherapy for Acute Myeloid Leukemia with a FLT3 Mutation. N Engl J Med 377 (5): 454-464, 2017. 11) Jones CL, et al: Inhibition of Amino Acid Metabolism Selectively Targets Human Leukemia Stem Cells. Cancer Cell 34 (5): 724-740 e4, 2018. 1) Papaemmanuil E, et al: Genomic Classification and Prognosis in Acute Myeloid Leukemia. N Engl J Med 374 (23): 2209-2221, 2016. 3) Assi R, Ravandi F: FLT3 inhibitors in acute myeloid leukemia: Choosing the best when the optimal does not exist. Am J Hematol 93 (4): 553-563, 2018. 10) Wilde L, Kasner M: Whom should we treat with novel agents? Specific indications for specific and challenging populations. Hematology Am Soc Hematol Educ Program 2021 (1): 24-29, 2021. 9) Thol F: What to use to treat AML: the role of emerging therapies. Hematology Am Soc Hematol Educ Program 2021 (1): 16-23, 2021. 8) Cortes JE, et al: Quizartinib versus salvage chemotherapy in relapsed or refractory FLT3-ITD acute myeloid leukaemia (QuANTUM-R): a multicentre, randomised, controlled, open-label, phase 3 trial. Lancet Oncol 20 (7): 984-997, 2019. 2) Jaiswal S, et al: Age-related clonal hematopoiesis associated with adverse outcomes. N Engl J Med 371 (26): 2488-2498, 2014. 6) Pollyea DA, et al: NCCN clinical practice guidelines in oncology, Acute myeloid leukemia, version 1. 2022. 2022: https://www.nccn.org/professionals/physician_gls/pdf/aml.pdf. 4) Kiyoi H, et al: FLT3 mutations in acute myeloid leukemia: Therapeutic paradigm beyond inhibitor development. Cancer Sci 111 (2): 312-322, 2020. 7) Perl AE, et al: Gilteritinib or Chemotherapy for Relapsed or Refractory FLT3-Mutated AML. N Engl J Med 381 (18): 1728-1740, 2019. |
| References_xml | – reference: 9) Thol F: What to use to treat AML: the role of emerging therapies. Hematology Am Soc Hematol Educ Program 2021 (1): 16-23, 2021. – reference: 5) Stone RM, et al: Midostaurin plus Chemotherapy for Acute Myeloid Leukemia with a FLT3 Mutation. N Engl J Med 377 (5): 454-464, 2017. – reference: 11) Jones CL, et al: Inhibition of Amino Acid Metabolism Selectively Targets Human Leukemia Stem Cells. Cancer Cell 34 (5): 724-740 e4, 2018. – reference: 12) Wei AH, et al: Venetoclax plus LDAC for newly diagnosed AML ineligible for intensive chemotherapy: a phase 3 randomized placebo-controlled trial. Blood 135 (24): 2137-2145, 2020. – reference: 2) Jaiswal S, et al: Age-related clonal hematopoiesis associated with adverse outcomes. N Engl J Med 371 (26): 2488-2498, 2014. – reference: 4) Kiyoi H, et al: FLT3 mutations in acute myeloid leukemia: Therapeutic paradigm beyond inhibitor development. Cancer Sci 111 (2): 312-322, 2020. – reference: 6) Pollyea DA, et al: NCCN clinical practice guidelines in oncology, Acute myeloid leukemia, version 1. 2022. 2022: https://www.nccn.org/professionals/physician_gls/pdf/aml.pdf. – reference: 3) Assi R, Ravandi F: FLT3 inhibitors in acute myeloid leukemia: Choosing the best when the optimal does not exist. Am J Hematol 93 (4): 553-563, 2018. – reference: 7) Perl AE, et al: Gilteritinib or Chemotherapy for Relapsed or Refractory FLT3-Mutated AML. N Engl J Med 381 (18): 1728-1740, 2019. – reference: 8) Cortes JE, et al: Quizartinib versus salvage chemotherapy in relapsed or refractory FLT3-ITD acute myeloid leukaemia (QuANTUM-R): a multicentre, randomised, controlled, open-label, phase 3 trial. Lancet Oncol 20 (7): 984-997, 2019. – reference: 1) Papaemmanuil E, et al: Genomic Classification and Prognosis in Acute Myeloid Leukemia. N Engl J Med 374 (23): 2209-2221, 2016. – reference: 10) Wilde L, Kasner M: Whom should we treat with novel agents? Specific indications for specific and challenging populations. Hematology Am Soc Hematol Educ Program 2021 (1): 24-29, 2021. |
| SSID | ssib043658134 ssj0066765 ssib002821954 ssib005879745 ssib007485360 ssib058493862 ssib000940260 ssib002484664 |
| Score | 2.326792 |
| Snippet | 急性骨髄性白血病（acute myeloid leukemia：AML）の分子病態の解明により，種々の新規分子標的薬が開発されている．FLT3阻害薬やIDH1/2阻害薬のように特定のドライバー遺... |
| SourceID | jstage |
| SourceType | Publisher |
| StartPage | 1186 |
| SubjectTerms | 個別化医療 分子標的 急性骨髄性白血病 抗体医薬 |
| Title | 急性骨髄性白血病に対する分子標的治療薬 |
| URI | https://www.jstage.jst.go.jp/article/naika/111/6/111_1186/_article/-char/ja |
| Volume | 111 |
| hasFullText | 1 |
| inHoldings | 1 |
| isFullTextHit | |
| isPrint | |
| ispartofPNX | 日本内科学会雑誌, 2022/06/10, Vol.111(6), pp.1186-1192 |
| journalDatabaseRights | – providerCode: PRVAFT databaseName: Colorado Digital library customDbUrl: eissn: 1883-2083 dateEnd: 99991231 omitProxy: true ssIdentifier: ssib007485360 issn: 0021-5384 databaseCode: KQ8 dateStart: 19130101 isFulltext: true titleUrlDefault: http://grweb.coalliance.org/oadl/oadl.html providerName: Colorado Alliance of Research Libraries |
| link | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwpR1NaxNBdKkVxIv4id_04JwkNbMzO_MGT7vphqJUEFroLWS_wByiSHrxlJYqghdPSrx5EItVBK-ifyYkaf-F781uNhv1YCssy2TmzfuYN-G9t8y85zi3Uoi0RLNQ421X1dBee7UoolPmaK484fIUBF1wXnugVjfkvU1vc-FEv3JqaasXLcfP_nqv5DhaxT7UK92SPYJmS6TYgW3UL75Rw_j-Jx2zUNFJBd-bNjQLDfN95oNtBAxkZUgzY1iwwkJgPqdO6tEMcLpAj5LgQ4_5TRaERQ_CU8NlYIcAGCgLs8JMnTAjIYJBPH5BK3BZEBS0cCLSMgjWqDrBBIZ0c7ZNA0ctcmU50cSq4QUVH8lJFjQIP0pkAjsEJCOU33ctbEhPiQ83jv2BaJuWK4QwM3igbvCJWmBIUAvvkVBgLH6kaKpfRDCYplJC9XIPW77AriLQwpAQyLu0i-cRp76wlAVxQcA-PrePJ3vVtuCOR_ORfx5Jc3MCIHDH5qV6SntTWJdHf1gPDPZUxRPhPC8T-LuVc7miJLFdumNGJm95Nm8uc3ixL1sWkEK9lrJvAm9NB-lyX6uDEcZJF-0iFT-5_7DioBtJSecqDh3M1SPAgJ1XEwp6oE21foKW6A7O5kuBDi-fJSRE79cIUGXCNzpwndccKdYyT7NKAt-ZFxcdxg6GT9Ojl9YbXD_rnCnCuCU_F--cs9Bpn3dOrRUHVS44Ztz_MO5_PPy0d7i_i43J4MfB-_7k7fPh9v7o68_h9mC482r08sXoy-vx3mDybnf87ftksHPw5vNFZ6MZrjdWa0WVkloHYwNRi-tJImORJTH34kxkkAkMEZRKIFE6Qf8bUte0ecplnEpNAU6cZpBILWQGkIC45Cx2H3fTy86SrmuVtV1ej3QsUzeORCoRHfBYUZpJfcW5mwvdepKnomkdRcVX_2v2Nef07L923VnsPd1Kb6A_3otu2i3zC92ZrfU |
| linkProvider | Colorado Alliance of Research Libraries |
| openUrl | ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=%E6%80%A5%E6%80%A7%E9%AA%A8%E9%AB%84%E6%80%A7%E7%99%BD%E8%A1%80%E7%97%85%E3%81%AB%E5%AF%BE%E3%81%99%E3%82%8B%E5%88%86%E5%AD%90%E6%A8%99%E7%9A%84%E6%B2%BB%E7%99%82%E8%96%AC&rft.jtitle=%E6%97%A5%E6%9C%AC%E5%86%85%E7%A7%91%E5%AD%A6%E4%BC%9A%E9%9B%91%E8%AA%8C&rft.au=%E5%AE%AE%E6%9C%AC%2C+%E6%95%8F%E6%B5%A9&rft.au=%E8%8F%8A%E7%B9%81%2C+%E5%90%89%E8%AC%99&rft.date=2022-06-10&rft.pub=%E4%B8%80%E8%88%AC%E7%A4%BE%E5%9B%A3%E6%B3%95%E4%BA%BA+%E6%97%A5%E6%9C%AC%E5%86%85%E7%A7%91%E5%AD%A6%E4%BC%9A&rft.issn=0021-5384&rft.eissn=1883-2083&rft.volume=111&rft.issue=6&rft.spage=1186&rft.epage=1192&rft_id=info:doi/10.2169%2Fnaika.111.1186&rft.externalDocID=article_naika_111_6_111_1186_article_char_ja |
| thumbnail_l | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=0021-5384&client=summon |
| thumbnail_m | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=0021-5384&client=summon |
| thumbnail_s | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=0021-5384&client=summon |